Trending Anti-E7 Serology Predicts Mortality and Recurrence of HPV-Associated Cancers of the Oropharynx
Journal of Oncology · 26.09.2022 · 2022 · 1-6
DOI: 10.1155/2022/3107990 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Oncology, erschienen am 26.09.2022. Verfasst von Luke Johnson und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Louisville School of Medicine, KY 40202, USA. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIH NCI, University of Louisville.
Abstract (Originalsprache)
High-risk human papillomavirus (HPV) is among the most common causes of head and neck cancer (HNC) with increasing incidence. HPV-associated HNC patients’ clinical response to treatment varies drastically, which has made treatment de-escalation clinical trials challenging. To address the need for noninvasive biomarkers that differentiate patient outcomes, serum antibodies to E7 oncoprotein levels were evaluated in serial serum specimens from HPV-positive HNC patients ( n = 48 ). We have found that increasing antibodies to E7 throughout treatment correlates with increased cancer recurrence or progression to mortality ( p = .004 ) with 100% specificity as a predictive test.
Autor:innen und Institutionen
- Department of Medicine, University of Louisville School of Medicine, KY 40202, USA.
- Brown Cancer Center, University of Louisville School of Medicine, KY 40202, USA.
- John T Milliken Department of Internal Medicine, Washington University School of Medicine in St. Louis, MO 63110, USA.
- Center for Cancer Immunology, Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
- Cutaneous Biology Research Center, Department of Dermatology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
ORCID-Profile: Luke Johnson, Dat T Ha, Gregory Shoemaker, Paul A Bevins, John Strickley, Shadmehr Demehri, Rebecca A Redman, Joongho Joh
Förderung
- NCI NIH HHS
- NIH NCI
- University of Louisville
- James Graham Brown Cancer Center
- Dr. Alfred B Jenson for Head and Neck Cancer Research
Zitieren
APA
Johnson, L., Ha, D. T., Hall, M. B., Shoemaker, G., Bevins, P. A., Strickley, J., Demehri, S., Redman, R. A., & Joh, J. (2022). Trending Anti-E7 Serology Predicts Mortality and Recurrence of HPV-Associated Cancers of the Oropharynx. Journal of Oncology, 2022, 1-6. https://doi.org/10.1155/2022/3107990
Vancouver
Johnson L, Ha DT, Hall MB, Shoemaker G, Bevins PA, Strickley J, et al. Trending Anti-E7 Serology Predicts Mortality and Recurrence of HPV-Associated Cancers of the Oropharynx. Journal of Oncology. 2022;2022:1-6. doi:10.1155/2022/3107990
BibTeX
@article{Johnson2022,
author = {Johnson, Luke and Ha, Dat T and Hall, Melissa B and Shoemaker, Gregory and Bevins, Paul A and Strickley, John and Demehri, Shadmehr and Redman, Rebecca A and Joh, Joongho},
title = {Trending Anti-E7 Serology Predicts Mortality and Recurrence of HPV-Associated Cancers of the Oropharynx},
journal = {Journal of Oncology},
year = {2022},
volume = {2022},
pages = {1--6},
doi = {10.1155/2022/3107990}
}
EUVIMED